Immuneering Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.87 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.91, a 155.73% increase year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.92, a 68.52% decline year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.10, a 29.24% increase year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.72, a 53.27% decline year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.01, a 45.23% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.67, a 32.16% decline from fiscal 2023.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.41, a 44.96% decline from fiscal 2022.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.83, a 2.38% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.87 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $4.91 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.01 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $1.99 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.89 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $1.92 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $3.67 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $3.69 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $3.69 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $6.10 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $5.41 10-K · filed 2024-03-01 | |||
| 2023-09-30 | $5.31 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $5.23 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $4.72 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $9.83 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $9.39 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $9.50 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $10.10 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $10.07 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $9.56 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $8.66 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |